Published in Healthcare Finance, Tax and Law Weekly, July 18th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Merck Serono International SA.
Report 1: Merck Serono S.A. (virt-x: SEO) announced that Phase III data on safinamide, a new agent in Phase III development for the treatment of Parkinson's disease symptoms, were presented by Professor Fabrizio Stocchi at the American Academy of Neurology 59th Annual Meeting in Boston, Massachusetts, USA. These data are from a 6-month (24 weeks), randomized, double blind, placebo-controlled, international trial.
"These data are promising...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly